About: Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dose reduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and 68. Background & Aims Peginterferon plus ribavirin has been the standard of care for chronic hepatitis C for a decade and an essential component of combination regimens for this disease. This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin. Methods Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 mmg/week and ribavirin 800 mg/day or 1000/1200 mg/day. All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter. Non-SAEs of special interest included those leading to dose reduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs. Results Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and 68. (en)
Title	Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients (en)
skos:prefLabel	Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients (en)
skos:notation	RIV/00216224:14110/12:00061655!RIV13-MSM-14110___
http://linked.open...avai/predkladatel	Lékařská fakulta
http://linked.open...avai/riv/aktivita	S
http://linked.open...avai/riv/aktivity	S
http://linked.open...iv/cisloPeriodika	8
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Husa, Petr
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	166650
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/12:00061655
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	chronic hepatitis C; pegylated interferon; ribavirin; treatment (en)
http://linked.open.../riv/klicoveSlovo	treatment pegylated interferon ribavirin chronic hepatitis C
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[4E27871166AA]
http://linked.open...i/riv/nazevZdroje	Liver International
http://linked.open...in/vavai/riv/obor	FN
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	14 (xsd:int)
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	32
http://linked.open...iv/tvurceVysledku	Husa, Petr Ferenci, Peter Berak, Hanna Dusheiko, Geoffrey M. Gane, Edward J. Hadziyannis, Stephanos J. Han, Kwang-Hyub Harley, Hugh A. Heathcote, Jenny E. Horsmans, Yves J. Lee, Samuel S. Messinger, Diethelm Roberts, Stuart K. Tatsch, Fernando
http://linked.open...ain/vavai/riv/wos	000307722000011
issn	1478-3223
number of pages	8 (xsd:int)
http://bibframe.org/vocab/doi	10.1111/j.1478-3231.2012.02819.x
http://localhost/t...ganizacniJednotka	14110
is http://linked.open...avai/riv/vysledek of	Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software